Grant: CIHR Fellowship
Direct Payment
$100,000.00
Understanding Mechanisms of Plasticity and State Determination in Glioblastoma
EF 2021-22
Résumé
Glioblastoma, the most common adult brain cancer, kills approximately 13,000 North Americans every year, between one and two years after they have been diagnosed. Yet, the treatments for this disease have remained the same for the last 20 years: surgery to remove the bulk of the cancer, followed by radiation therapy and standard chemotherapy to attempt to kill the remaining cancer cells invading the brain. Efforts to discover new and more effective treatments have all failed due to the multiple cancer cell types that exist in each patient's tumor and their ability to interconvert, a process called plasticity. Indeed, we recently discovered that the cancer is made up of many types of cells that mirror those found in the normal brain: cancer stem cells that give rise to other cell types like cancer-like neurons and astrocytes. Unfortunately, chemotherapy, radiation, and many of the most recent promising cancer therapies are ineffective against some of these cell types. We urgently need to understand how to target each cancer cell type, and what drives a brain cancer cell to change or maintain its cell type.
Backed by the expertise and extensive resources available across the Massachusetts Institute of Technology, the Broad Institute, and the Boston medical community, we will develop and use state-of-the-art genomics technologies to approach this problem from three sides: (1) we will characterize the dynamics of the state transitions between cancer cells; (2) we will identify how genes regulate these transitions; and, (3) we will decipher the effects of environmental factors on these transitions. Together, these approaches will yield unprecedented insight into the mechanisms which regulate the fate decisions of cancer cells.
We will leverage these findings to develop a new class of therapeutics - plasticity modifiers - to prevent cancer cells from changing cell type. This will make the cancer more uniform and easier to kill using chemotherapy and targeted therapies.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
454951
Name
Couturier Charles P
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Understanding Mechanisms of Plasticity and State Determination in Glioblastoma
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Brain Cancer; Crispr Screen; Glioblastoma; Lineage Tracing; Nascent Rna; Plasticity; Single-Cell Rna-Seqencing
Abstract
Glioblastoma, the most common adult brain cancer, kills approximately 13,000 North Americans every year, between one and two years after they have been diagnosed. Yet, the treatments for this disease have remained the same for the last 20 years: surgery to remove the bulk of the cancer, followed by radiation therapy and standard chemotherapy to attempt to kill the remaining cancer cells invading the brain. Efforts to discover new and more effective treatments have all failed due to the multiple cancer cell types that exist in each patient's tumor and their ability to interconvert, a process called plasticity. Indeed, we recently discovered that the cancer is made up of many types of cells that mirror those found in the normal brain: cancer stem cells that give rise to other cell types like cancer-like neurons and astrocytes. Unfortunately, chemotherapy, radiation, and many of the most recent promising cancer therapies are ineffective against some of these cell types. We urgently need to understand how to target each cancer cell type, and what drives a brain cancer cell to change or maintain its cell type.
Backed by the expertise and extensive resources available across the Massachusetts Institute of Technology, the Broad Institute, and the Boston medical community, we will develop and use state-of-the-art genomics technologies to approach this problem from three sides: (1) we will characterize the dynamics of the state transitions between cancer cells; (2) we will identify how genes regulate these transitions; and, (3) we will decipher the effects of environmental factors on these transitions. Together, these approaches will yield unprecedented insight into the mechanisms which regulate the fate decisions of cancer cells.
We will leverage these findings to develop a new class of therapeutics - plasticity modifiers - to prevent cancer cells from changing cell type. This will make the cancer more uniform and easier to kill using chemotherapy and targeted therapies.
Competitiondate
202110
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Couturier, Charles P
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~